Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The addition of an anti-inflammatory agent could be a valid option for controlling choroidal
neovascularization, as simply inhibiting VEGF addresses neither the multifactorial
pathogenesis of choroidal neovascularization nor the underlying cause of VEGF production.